Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

54.73 +0.45 (+0.84%)
Streaming Delayed Price Updated: 10:57 AM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
86 87 Next >
News headline image
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus Pharmaceuticals (NASDAQ:SUPN) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Jim Cramer Praises Lowe's CEO, As For CrowdStrike: 'I'll See You At $1000' ↗
On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings. 
Via Benzinga
News headline image
Winners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Q1 Earnings Recap: Bristol-Myers Squibb (NYSE:BMY) Tops Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Retail Chatter On BMY Doubles In 24 Hours With Drug Failing To Meet Primary Goal: Here's What Investors Are Thinking ↗
Via Stocktwits
Bristol Myers, Pfizer To Offer Blood Thinning Drug At Discount: Retail Chatter Around BMY Jump 60% In 24 Hours ↗
Via Stocktwits
News headline image
Peering Into Bristol-Myers Squibb's Recent Short Interest ↗
 
Via Benzinga
News headline image
A Look Into Bristol-Myers Squibb Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US ↗
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs. 
Via Benzinga
Topics Government
News headline image
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock ↗
The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment. 
Via Investor's Business Daily
News headline image
FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks ↗
Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval. 
Via Benzinga
News headline image
3 Value Stocks We’re Skeptical Of
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial ↗
Bristol Myers' Reblozyl missed its primary goal in a Phase 3 anemia trial but showed positive secondary outcomes in myelofibrosis patients. 
Via Benzinga
News headline image
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
From Bristol Myers Squibb
Via Business Wire
News headline image
Unpacking Q1 Earnings: Organon (NYSE:OGN) In The Context Of Other Branded Pharmaceuticals Stocks
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off ↗
Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and nationwide delivery. 
Via Benzinga
News headline image
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - An Undervalued Stock with Strong Fundamentals ↗
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) is an undervalued pharmaceutical stock with strong profitability, a high dividend yield, and attractive valuation metrics, making it a candidate for value investors. 
Via Chartmill
News headline image
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
From Bristol Myers Squibb
Via Business Wire
News headline image
Don’t Miss These 4 Stocks With Explosive Dividend Yields ↗
Via MarketBeat
Topics Stocks
News headline image
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? ↗
BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating. 
Via Benzinga
News headline image
1 Safe-and-Steady Stock with Exciting Potential and 2 to Brush Off
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
Why Bristol-Myers Squibb (BMY) Shares Are Sliding Today
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious analyst note from UBS highlighting significant upcoming expenses and other... 
Via StockStory
Topics ETFs Intellectual Property Stocks
News headline image
Top S&P500 movers in Friday's session ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
News headline image
What's going on in today's session: S&P500 movers ↗
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
News headline image
Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday? ↗
MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in gastric cancer using its iNKT cell therapy, agenT-797, in combination with... 
Via Benzinga
News headline image
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
News headline image
2 Top Stocks Down 16% and 17% This Year to Buy and Hold ↗
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
86 87 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.